Bruce Power receives regulatory approval to produce medical Lu-177

September 29, 2021, 9:27AMNuclear News
The Bruce nuclear power plant in Ontario, Canada. (Photo: Bruce Power)

Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to begin the production of lutetium-177, becoming the first power reactor globally to commercially produce the medical radioisotope. Isogen, a joint venture between Framatome and Kinectrics, will produce Lu-177 at Bruce’s eight-unit CANDU nuclear power plant in Ontario, Canada, using Isogen’s isotope production system (IPS).